Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives

Table 2 Metabolic monitoring guidelines as proposed by various organizations

	US consensus[32]	BAP guidelines[86]
Weight	At 4 wk, 8 wk, and 12 wk after initiating or changing SGA therapy, then quarterly	BMI weekly for the first 4–6 wk, then every 2–4 wk for up to 12 wk. At a minimum, once every 4 wk for the first 12 wk, then at 6 mo and at least annually
Blood glucose	Assessed fasting plasma glucose at 3 mo, then annually	Assessed fasting or random plasma glucose in the initial weeks and glycated hemoglobin at 12 wk, 6 mo, and then annually
Lipid profile	At 3 mo, then repeated at 5-yr intervals if normal	At 12 wk, 6 mo, and then annually. The total cholesterol/high-density lipoprotein cholesterol ratio should be required.
Blood pressure	At 3 mo, then annually	At 12 wk, 6 mo, and then annually

US consensus: Consensus proposed by American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity[32]; BAP guidelines: Guidelines proposed by the British Association for Psychopharmacology[86]; SGA: Second-generation antipsychotics; BMI: Body mass index.